Home
Live Updates
GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) : comparemela.com
GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
Study of uproleselan combined with chemotherapy did not meet its primary endpoint of overall survival in the intent to treat population
Adverse events were consistent with known side effect...
Related Keywords
China ,
United States ,
Chinese ,
Harout Semerjian ,
Drug Administration ,
Alliance For Clinical Trials In Oncology ,
Nasdaq ,
Exchange Commission ,
Glycomimetics Inc ,
Chinese National Medical Products Administration ,
Chief Executive Officer ,
Clinical Trials ,
First Quarter ,
Breakthrough Therapy ,
Fast Track ,
Bone Marrow ,
Biohealth Capital ,
Annual Report ,
Markets ,
comparemela.com © 2020. All Rights Reserved.